Eteplirsen is currently approved by the FDA for use in patients with a confirmed mutation of the dystrophin gene amenable to exon 51 skipping. While its primary use is in pediatric patients, it is not specifically approved for use in neonates. Research is ongoing to determine its efficacy and safety in younger populations.
